BDAZ I totally agree with your take on Espr vs RVX as far as corporate communication/IR is concerned.  Any clarity regarding the trial would be great. Along those lines, it’s hard to understand why senior management can’t release a few bits of information such as how many total events have occurred and/or what some of the average gross (blinded) data points for the trial population are so investors can make some of their own assessments as to how the trial is progressing.